Who Should Not Take Tirzepatide? Key Considerations

Photo by https://kaboompics.com/ via Pexels

Quick Answer

Tirzepatide is not suitable for everyone. People with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take it. People with a history of pancreatitis should discuss the risks and alternatives with a healthcare professional before starting treatment.

Overview of Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in eligible adults. It works by enhancing insulin secretion, slowing gastric emptying, and reducing appetite. In the 40-week SURPASS-2 trial, HbA1c fell by 2.01–2.30 percentage points across tirzepatide doses, and body-weight reductions were 1.9–5.5 kg greater than with semaglutide 1 mg^[1].

However, like all medications, tirzepatide isn't suitable for everyone. Understanding who should not take tirzepatide is crucial for ensuring patient safety and treatment efficacy. While the benefits are well-documented, certain underlying health conditions can make this medication inappropriate for some individuals.

Photo by Towfiqu barbhuiya via Pexels

Health Conditions Impacting Candidacy

Who Should Avoid Tirzepatide?

Certain health conditions can increase the risk of adverse effects when taking tirzepatide. Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should avoid this medication. The risk of developing thyroid C-cell tumors has been observed in rodent studies, prompting this precaution^[2]. In these studies, rodents developed thyroid C-cell tumors after receiving high doses of GLP-1 receptor agonists, highlighting a potential risk in humans, though the exact mechanism remains unclear.

Pancreatitis and Gallbladder Disease

People with a history of pancreatitis should discuss whether another treatment is more appropriate before using tirzepatide. Acute pancreatitis has been reported with this medication, although a meta-analysis of seven cardiovascular-outcome trials found no significant increase with GLP-1 receptor agonists compared with placebo^[3]. Additionally, individuals with gallbladder disease or a history of gallstones should be cautious, as GLP-1 receptor agonists can exacerbate these conditions by slowing bile flow and increasing the risk of gallstone formation.

Severe Gastrointestinal Disorders

Tirzepatide delays gastric emptying and may worsen symptoms of delayed stomach emptying. The current Zepbound prescribing information says the medication is not recommended for people with severe gastroparesis^[4]. People with severe gastrointestinal disease should discuss risks and alternatives with their healthcare provider.

Consultation and Professional Advice

Importance of Medical Consultation

Before starting tirzepatide, consulting a healthcare provider is crucial. They can assess individual health conditions and history to determine if this medication is appropriate. A comprehensive health evaluation, often involving blood tests and imaging studies, helps prevent potential complications and ensures the medication is tailored to the patient's needs. This approach aligns with guidelines from the American Diabetes Association, which emphasize personalized treatment plans^[5].

Monitoring and Adjustments

While on tirzepatide, regular monitoring is vital. Healthcare providers will track blood glucose levels, weight, and any side effects, adjusting the treatment plan as necessary. This regular check-in helps optimize the medication's benefits while minimizing risks. For instance, dose adjustments may be required if HbA1c targets are not met or if side effects persist. Using a GLP-1 medication tracker can simplify this process by logging doses and side effects, providing a comprehensive overview for both patients and healthcare providers.

Discussing Alternatives

If tirzepatide is not suitable, discussing alternative treatments with a healthcare provider is essential. Options may include other GLP-1 receptor agonists, such as semaglutide or dulaglutide, or different classes of diabetes medications like SGLT2 inhibitors. Each alternative has its own profile of benefits and risks, which should be considered in the context of the patient's overall health. For example, SGLT2 inhibitors like empagliflozin have been shown to reduce the risk of cardiovascular events by 14% in patients with type 2 diabetes, as reported in the EMPA-REG OUTCOME trial^[6].

Alternative Treatment Options

Other GLP-1 Receptor Agonists

For those who cannot take tirzepatide, other GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or dulaglutide (Trulicity) may be considered. These medications also promote insulin secretion and weight loss but may have different side effect profiles. The STEP 1 trial showed that semaglutide resulted in a 14.9% weight loss over 68 weeks, making it a viable alternative for weight management^[7]. Dulaglutide, on the other hand, has demonstrated cardiovascular benefits, reducing the risk of major adverse cardiovascular events by 12% in patients with type 2 diabetes and established cardiovascular disease, according to the REWIND trial^[8].

SGLT2 Inhibitors

SGLT2 inhibitors, such as empagliflozin or canagliflozin, offer another alternative for managing type 2 diabetes. These medications work by preventing glucose reabsorption in the kidneys, leading to glucose excretion through urine. They also provide cardiovascular benefits, making them suitable for patients with heart disease. The CANVAS Program found that canagliflozin reduced the risk of cardiovascular death, myocardial infarction, or stroke by 14%^[9]. Additionally, SGLT2 inhibitors have been shown to improve renal outcomes, making them a suitable option for patients with diabetic kidney disease.

Lifestyle Modifications

In addition to medication, lifestyle changes are critical for managing diabetes and weight. A balanced diet, regular physical activity, and weight management can significantly improve blood glucose levels and overall health. The Diabetes Prevention Program (DPP) study demonstrated that lifestyle interventions reduced the incidence of type 2 diabetes by 58% over three years^[10]. Patients are encouraged to work with healthcare professionals to develop a personalized plan that complements their medication regimen. This may include dietary counseling, exercise programs, and behavioral therapy to address emotional eating or stress management.

Frequently Asked Questions

What are the common side effects of tirzepatide?

Common side effects of tirzepatide include nausea, diarrhea, decreased appetite, and vomiting. These are usually mild to moderate in severity and tend to decrease over time as the body adjusts to the medication. However, any persistent or severe side effects should be reported to a healthcare provider. In clinical trials, up to 20% of patients reported experiencing nausea, highlighting the importance of starting at a low dose and titrating slowly^[11].

Can tirzepatide be used for weight loss alone?

Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in eligible adults. A 72-week trial found substantial weight reduction in adults with obesity who did not have diabetes^[12]. Whether it is appropriate depends on a person's medical history, other medications, and treatment goals, so patients should discuss its risks and benefits with a healthcare provider.

How does tirzepatide compare to semaglutide?

In the 40-week SURPASS-2 trial, tirzepatide produced greater HbA1c and body-weight reductions than semaglutide 1 mg. Across tirzepatide doses, HbA1c fell by 2.01–2.30 percentage points, and body-weight reductions were 1.9–5.5 kg greater than with semaglutide^[13]. The choice between the two should be based on individual health needs and clinician recommendations.

Is tirzepatide safe for individuals with kidney disease?

A clinical pharmacology study found no clinically relevant effect of renal impairment, including severe impairment and end-stage renal disease, on tirzepatide pharmacokinetics^[14]. People with kidney disease should still discuss monitoring and individual risks with their healthcare provider.

What should I do if I miss a dose of tirzepatide?

If you miss a dose of tirzepatide, take it as soon as you remember, unless it's close to your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take two doses at once. Always consult your healthcare provider for guidance if you miss a dose. It's also helpful to set reminders or use medication tracking apps to minimize the risk of missed doses.

Are there any interactions with other medications?

Tirzepatide may interact with other medications, particularly those affecting blood sugar levels. For example, combining tirzepatide with insulin or sulfonylureas can increase the risk of hypoglycemia. The prescribing information advises monitoring blood glucose and considering lower doses of insulin or sulfonylureas when these medicines are used together^[4]. Always inform your healthcare provider of all medications and supplements you are taking to avoid potential interactions.

Sources and References

[1] Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519

[2] DailyMed. "Zepbound (tirzepatide) prescribing information." DailyMed prescribing information

[3] Singh AK, et al. "Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials." Expert Rev Clin Pharmacol. 2020;13(4):461-468. https://doi.org/10.1080/17512433.2020.1736041

[4] DailyMed. "Zepbound (tirzepatide) prescribing information." DailyMed prescribing information

[5] American Diabetes Association. "Standards of Medical Care in Diabetes—2022." Diabetes Care. 2022;45(Suppl 1):S1-S264. https://diabetesjournals.org/care/article/45/Supplement_1/S1/138925/Standards-of-Medical-Care-in-Diabetes-2022

[6] Zinman B, et al. "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes." N Engl J Med. 2015;373:2117-2128. https://www.nejm.org/doi/full/10.1056/NEJMoa1504720

[7] Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

[8] Gerstein HC, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial." Lancet. 2019;394(10193):121-130. https://doi.org/10.1016/S0140-6736(19)31149-3

[9] Neal B, et al. "Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes." N Engl J Med. 2017;377:644-657. https://www.nejm.org/doi/full/10.1056/NEJMoa1611925

[10] Knowler WC, et al. "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin." N Engl J Med. 2002;346:393-403. https://www.nejm.org/doi/full/10.1056/NEJMoa012512

[11] Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519

[12] Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

[13] Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519

[14] Urva S, Quinlan T, Landry J, Martin J, Loghin C. "Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide." Clin Pharmacokinet. 2021;60(8):1049-1059. PubMed record

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare provider for diagnosis and treatment options tailored to individual health needs.